ReviewSeminars in immunology2016
Chimeric antigen receptor-redirected T cells return to the bench.
Review in Seminars in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- The potential of chimeric antigen receptor -T cell therapy for endocrine cancer.World journal of surgical oncology · 2025Review
- CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review).Molecular medicine reports · 2024Review
- Adoptive Immunotherapy and High-Risk Myeloma.Cancers · 2023Review
- CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.Biomolecules · 2023Review
- Co-Stimulatory Receptor Signaling in CAR-T Cells.Biomolecules · 2022Review
- A novel tumor-specific broad-spectral monoclonal antibody to PL2L60 is highly effective for the treatment of various types of cancers from human and mouse.American journal of cancer research · 2022Article
- Chimeric antigen receptor T-cell therapy for multiple myeloma.Frontiers in immunology · 2022Review
- CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- CAR T cell therapies for patients with multiple myeloma.Nature reviews. Clinical oncology · 2021Review
- CAR T cells and checkpoint inhibition for the treatment of glioblastoma.Expert opinion on biological therapy · 2020Review
- Silencing of theThe Journal of international medical research · 2019Article
- CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.Therapeutic advances in hematology · 2019Review
- Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.Current hematologic malignancy reports · 2018Review
- CAR T cell therapy for B-cell lymphomas.Best practice & research. Clinical haematology · 2018Review
- Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Protein & cell · 2017Review
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Enforced Expression of CXCR5 Drives T Follicular Regulatory-Like Features in Foxp3Biomolecules & therapeutics · 2017Article
- Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Bioscience reports · 2017Review
- Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.Frontiers in immunology · 2017Article
- Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
While the clinical progress of chimeric antigen receptor T cell (CAR-T) immunotherapy has garnered attention to the field, our understanding of the biology of these chimeric molecules is still emerging. Our aim within this review is to bring to light the mechanistic understanding of these multi-modular receptors and how these individual components confer particular properties to CAR-Ts. In addition, we will discuss extrinsic factors that can be manipulated to influence CAR-T performance such as choice of cellular population, culturing conditions and additional modifications that enhance their activity particularly in solid tumors. Finally, we will also consider the emerging toxicity associated with CAR-Ts. By breaking apart the CAR and examining the role of each piece, we can build a better functioning cellular vehicle for optimized treatment of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.